Why Ardelyx Inc Skyrocketed Higher Today
Ardelyx (NASDAQ: ARDX) stock rose 44% on Thursday after the company announced positive data from the phase 3 T3MPO-2 trial testing its irritable bowel syndrome drug, tenapanor, after the close of the bell last night.
Of the patients taking tenapanor, 36.5% were deemed responders, a statically significant increase over the 23.7% responder rate for patients taking placebo. Responders were defined as having at least a 30% reduction in abdominal pain and an increase of one or more complete spontaneous bowel movements in the same week for at least six of the 12 weeks of the treatment period.
Image source: Getty Images.
Source: Fool.com
Ardelyx Inc. Stock
€5.17
2.140%
With 1 Sell predictions and 1 Buy predictions the community sentiment towards the Ardelyx Inc. stock is not clear.
With a target price of 11 € there is potential for a 112.68% increase which would mean more than doubling the current price of 5.17 € for Ardelyx Inc..
